Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Childhood Rhabdomyosarcoma: early-phase trial registry
1 of 8 indexed Recurrent Childhood Rhabdomyosarcoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 1 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Recurrent Childhood Rhabdomyosarcoma: 8 US clinical trials tracked, 1 recruiting.
Recurrent Childhood Rhabdomyosarcoma is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 4 of these trials.
Enrollment posture brief
Registry condition recurrent-childhood-rhabdomyosarcoma
OPEN 1 | RECR 13% | LATE 0 | EARLY 6 | RANK #2176 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Acute Respiratory Infection (13% recruiting · 8 trials)
Recurrent Childhood Rhabdomyosarcoma lists 1 open slots (13% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Childhood Rhabdomyosarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Childhood Rhabdomyosarcoma is recruiting below its size-band peers.
1 of 8 indexed trials (12.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Childhood Rhabdomyosarcoma research.
National Cancer Institute (NCI) accounts for 4 of 8 trials (50%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Childhood Rhabdomyosarcoma trials plan to enrol fewer than 100 people.
Median target enrolment is 87 among the 8 trials that report a genuine target (sentinel values excluded). 5 of those (62.5%) plan for fewer than 100 participants.
-
Recurrent Childhood Rhabdomyosarcoma research is mostly interventional.
7 interventional and 1 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Florida International University
NCT05857969
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
NCT03155620
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NCT03210714
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Children's Oncology Group
NCT00919269
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
NCT00331643
Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
National Cancer Institute (NCI)
NCT01222715
Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
Children's Oncology Group
NCT00070109
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
Ann & Robert H Lurie Children's Hospital of Chicago
NCT01586104
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Childhood Rhabdomyosarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Childhood Rhabdomyosarcoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Childhood Rhabdomyosarcoma page
8 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Recurrent Childhood Rhabdomyosarcoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Recurrent Childhood Rhabdomyosarcoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Childhood Rhabdomyosarcoma condition card totals 8 registered trials; most-linked intervention Bone Marrow Aspiration and Biopsy; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.